Your Article Summary
See Latest ArticlesEffect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
Antimicrobial Agents and Chemotherapy, 06/30/09
Wenning LA et al. - Doubling the raltegravir dose to 800 mg when coadministered with rifampin therefore compensates for the effect of rifampin on raltegravir exposure but does not overcome the effect of rifampin on raltegravir trough concentrations. Coadministration of rifampin and raltegravir is not contraindicated; however, caution should be used, since raltegravir trough concentrations in the presence of rifampin are likely to be at the lower limit of clinical experience.
Related Articles
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways
Journal of Virology, 10/26/09
Relevance Score: 87%
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life
Journal of Clinical Virology, 10/13/09
Relevance Score: 84%
Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure
Antimicrobial Agents and Chemotherapy, 10/09/09
Relevance Score: 80%
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Chloroquine reduces arylsulphatase B activity and increases chondroitin 4-sulphate: implications for mechanisms of action and resistance
Malaria Journal, 12/18/09
Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infection: a meta-analysis
Current Medical Research and Opinion, 12/17/09
Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins
Expert Review of Anti-infective Therapy, 12/17/09